Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.

NCT06659653 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia

Interventions

DRUG: PRG2302

Sponsor

Tan Jie

Collaborators

[object Object]